N/A N=412 Group Therapy for Nicotine Dependence: Mindfulness and Smoking
Smoking · Tobacco Use Cessation
Primary: Number of Participants With Smoking Abstinence — 21; 39; 43 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=433 A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation
Agitation Associated With · Alzheimer's Disease · Alzheimer's Type
Primary: Change From Baseline In The Cohen-Mansfield Agitation Inventory (CMAI) Total Score After 12 Weeks Of Brexpiprazole Treatment — -21.6; -17.6; -17.8 units on a scale…
Phase 4 N=102 A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures
Epilepsy With Partial On-set Seizures
Primary: The Number of Subjects Completing 24 Weeks Adjunctive Therapy During Maintenance Phase — 36; 37 participants
N/A N=100 Evaluation of Video Laryngoscopy in Patients With Head and Neck Pathology
Difficult Intubation
Primary: Number of Participants With Cormack-Lehane Grade >2 Obtained With CMAC D Blade — 37 Participants
Phase 4 N=237 Extended-Release vs. Oral Naltrexone Alcohol Treatment in Primary Care
Alcohol Dependence
Primary: Percentage of Participants With Alcohol Abstinence or Moderate Drinking — 29; 23 percentage of participants
N/A N=267 Effectiveness of Medicorp HO Preparatory Course
Psychological Stress · Depressive Symptoms · Anxiety State
Primary: Change in Confidence Level — 2.18; 3.50; 3.79 score on a scale
N/A N=78 Aerobic Exercise and Cognitive Training in Older Adults
Sedentary Lifestyle
Primary: Change Executive Language Functions (Category Verbal Fluency) — 5; -1 Number of Fluent Words within 60 seconds
N/A N=47 Focused Cardiac Ultrasound
Ventricular Dysfunction · Pericardial Effusion · Valvular Disease
Primary: Number of Patients Detected With Ventricular Dysfunction, Pericardial Effusion, Valvular Disorders, Septal Disorders, and Coronary Anomalies. — 13; 13; 9; 4 Participants
Phase 4 N=11 Effect of an H1 Receptor Antagonist on Exercise Performance in Hypoxia
Hypoxia, Altitude
Primary: Performance Time — 17.03; 18.08; 16.32 minutes — p=0.047
Phase 2 N=90 Prospective Evaluation of Budesonide for Prevention of Esophageal Strictures After Endotherapy
Esophageal Stricture
Primary: Dysplasia in Barrett Esophagus (BE) — 4; 4; 3; 23 Participants — p=0.992
Early Phase 1 N=12 Evaluation of Bioavailability of Diclofenac Dermal Products
Bioavailability
Primary: Serum Diclofenac Concentrations — 5.6; 40.0 ng/mL
Phase 3 N=114 Efficacy of Tranexamic Acid and Epsilon-aminocaproic Acid in Reducing Bleeding and Transfusions in Cardiac Surgery
Bleeding
Primary: Chest Tube Drainage — 200; 225; 375; 400 mL
Phase 3 N=1,044 A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation
Cystic Fibrosis
Primary: Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 995; 351…
Phase 3 N=92 A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency
Adult Growth Hormone Deficiency · Growth Hormone Disorder
Primary: Incidence of Adverse Events — 530.8; 514.2 Events per 100 patient years
Phase 2 N=34 Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in OSA
Obstructive Sleep Apnea · Excessive Sleepiness
Primary: Standard Deviation of Lateral Position (SDLP) at 2 Hours Post-dose (Approximately at Tmax) — 19.92; 18.83 centimeter (cm) — p=0.0062